ITALVACUUM will participate in EXPOQUIMIA 2026, taking place in Barcelona from 2 to 5 June, where the company will present its vacuum drying technologies developed for pharmaceutical and ...

The WHO has classed this outbreak as “extraordinary” due to the lack of therapeutic options and epidemiological trends.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline ATTR-CM.

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS.

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.